ClinicalTrials.gg
Active, not recruitingNCT07562438Updated Oct 27, 2026

Phase 2 Clinical Trial of 177Lu-P17-088 for mAPMR Prostate Cancer

A Phase 2 interventional study of 177Lu-P17-088 in Prostate Cancer, sponsored by First Affiliated Hospital of Fujian Medical University. Active, not recruiting at 1 site in China. Open to male participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by First Affiliated Hospital of Fujian Medical University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now Active, not recruitingPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University — 10 open to participants now, 13 under way, 1 of them phase 3. Prostatic Neoplasms · First Affiliated Hospital of Fujian Medical University.

Enrollment
9th of 13
25 · median 40
Started
2026
with 1 other
Phase 2
3 of 15
none open now
Primary completion
2027-06
later than 11 of 12 live
Registered
14th of 15
by date

Among the 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 11 of the 12 other live ones, and was the 14th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

10 of the 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 90 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University, or all of them as a file.
02

Study summary

PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. P17-088 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 177Lu-labeled P17-088 for treating patients with PSMA-positive metastatic androgen pathway modulation resistant (mAPMR) prostate cancer.

Read the detailed description

Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) has demonstrated promising potential for the treatment of metastatic androgen pathway modulation resistant (mAPMR) prostate cancer. Conjugation of albumin-binding moieties to PSMA-targeted radioligands can prolong their circulating half-life in the blood, thereby markedly enhancing tumor uptake and therapeutic efficacy. P17-088 incorporates a pegylated p-iodophenylbutanoyl group as an albumin binder with moderate binding affinity yet superior overall performance, which achieves a refined balance between augmented tumor accumulation and favorable safety profiles.

In our preliminary first-in-human study, 177Lu-P17-088 was observed to exhibit elevated distribution in organs including the red bone marrow and kidneys, with a considerably higher accumulation magnitude in tumor lesions. Satisfactory therapeutic outcomes were achieved even at a low activity dose of 1.11 GBq, validating its potential for further clinical translational research.

This single-arm study is designed to further evaluate the safety and efficacy of low-dose 177Lu-P17-088 in mAPMR prostate cancer patients. 177Lu-P17-088 will be administered at a fixed activity of 3.7 GBq (±10%) once every 6 to 8 weeks, with a total of four planned treatment cycles.

Post-treatment follow-up (safety and efficacy): Upon discontinuation of treatment, all enrolled participants will undergo systematic safety surveillance, including a 30-day short-term safety follow-up (FUP) assessment and extended long-term safety monitoring for approximately 12 months.

Survival follow-up: Following the termination of study treatment or completion of the post-treatment follow-up period, participants' vital status will be collected via telephone contact every 90 days as part of survival surveillance. Strict adherence to the survival follow-up schedule shall be ensured to facilitate complete survival data acquisition. Survival follow-up and the overall study will be concluded once the required number of overall survival (OS) events for the final survival analysis is reached.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. androgen pathway modulation resistant (mAPMR) prostate cancer refers to Prostate cancer with distant metastases and sustained castrate testosterone (\< 50 ng/dL or 1.7 nmol/L) during APM therapy, meeting ≥1 criterion:

    • PSA nadir ≥1.0 ng/mL, absolute PSA rise ≥0.2 ng/mL confirmed ≥21 days apart;
    • Radiographic progression: 1.1 soft tissue progression, or bone scan progression per PCWG4 2+2 rule (≥6 new bone lesions confirmed on single scan); PSMA-PET new metastatic lesions also qualify as progression.
  2. Failure of, Refusal of, Absence of, or Refractoriness to Standard Therapy, or Disease Progression, or No Available Standard Therapy per Current Guidelines:

    • Patients who have not received, refused, or progressed after receiving at least 1 but no more than 2 prior taxane-based therapies. The taxane regimen must have included exposure for at least 2 cycles. Patients who received only one taxane may be included if the investigator deems them unsuitable for a second taxane (e.g., due to frailty assessed by geriatric/comorbidity evaluation or intolerance).
    • Patients who have progressed after receiving at least one novel androgen axis drug [NAAD] (e.g., abiraterone, enzalutamide).
  3. Ability to understand and voluntarily sign a written form (ICF), and willingness and ability to comply with trial procedures including examinations and follow-up.
  4. Age 18-90 years (inclusive).
  5. Expected survival > 6 months.
  6. performance status ≤ 2.
  7. Presence of high-uptake lesions confirmed by 68Ga-PSMA-11 PET/CT imaging (positive defined as lesion uptake >1.5 times the liver background).
  8. At least one measurable soft tissue lesion per RECIST version 1.1 criteria, OR at least one bone metastasis on bone scintigraphy, OR at least one PSMA-positive metastatic lesion on PSMA-PET/CT, all as defined by PCWG4.
  9. Adequate organ function (No blood products, growth factors, or albumin administered within 14 days prior to baseline lab tests):

    • Bone Marrow Function: ≥ 1.5 × 10\^9/L, White blood cell count ≥ 3.0 × 10\^9/L, count ≥ 100 × 10\^9/L, ≥ 10 g/dL (≥ 100 g/L).
    • Liver Function: Albumin ≥ 30 g/L, Total ≤ 1.5 × , or AST ≤ 3.0 × ULN (without liver metastases) or ≤ 5.0 × ULN (with liver metastases).
    • Renal Function: Serum creatinine ≤ 1.5 × ULN.
  10. Agreement to comply with prescribed radiation protection measures during the trial period.

Exclusion criteria

Exclusion Criteria:

  1. Inability to tolerate imaging procedures;
  2. Patients who have received systemic anticancer therapy (e.g., chemotherapy, radiotherapy, immunotherapy; excluding endocrine therapy), drugs, or device therapy within 4 weeks prior to dosing;
  3. Patients who received radionuclide therapy (Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, Lutetium-177) within 6 months, or any External Beam Radiation Therapy (EBRT) within 2 months prior to the first dose;
  4. Patients with unresolved Grade 4 myelosuppression from prior anticancer therapy within 2 weeks, or Grade 3 myelosuppression requiring >6 weeks for recovery;
  5. Planned use of cytotoxic chemotherapy, antitumor immunotherapy, radioligand therapy, or similar agents during the study;
  6. Use of blood products or albumin within 14 days before dosing to meet enrollment criteria;
  7. at screening, except:

    • Asymptomatic cases confined to supratentorial/cerebellar regions (no midbrain/pons/medulla/spinal cord involvement) without therapy and with lesions ≤1.5 cm;
    • Symptomatic cases with treated and radiologically stable lesions (>4 weeks);
  8. Other within 5 years (excluding cured localized cancers like basal/squamous cell skin carcinoma);
  9. Superscan on bone scintigraphy;
  10. Symptomatic or impending spinal cord compression;
  11. Prior EBRT involving extensive bone marrow (>25%);
  12. Significant cardiac disease at screening, including:

    • >470 ms or long QT syndrome history;
    • Myocardial infarction, angina, or CABG within 6 months deemed ineligible by investigators;
  13. Any condition that, per investigator judgment, may compromise safety, data interpretation, or indicate high risk;
  14. Uncontrolled bladder outlet obstruction, urinary incontinence, claustrophobia, or radiophobia at screening;
  15. Positive for -Ab, , or syphilis antibodies at screening;
  16. -positive patients with active HBV replication (confirmed by HBVDNA per investigator assessment);
  17. Known allergy to proteins/peptides, , or structurally related compounds;
  18. History of drug/alcohol abuse within 1 year or chronic substance abuse;
  19. Failure to use effective during the trial and for 6 months post-last dose;
  20. Severe active infection prior to the first administration.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    177Lu-P17-088

    Participant will receive 3.7 GBq (+/- 10%) 177Lu-P17-088, once every 6-8 weeks for a planned 4 cycles

    Drug: 177Lu-P17-088

Interventions

  • Drug177Lu-P17-088

    administered intravenously once every 6-8 weeks (1 cycle) for 4 cycles

06

What researchers measure

Primary outcomes

  1. Prostate-specific antigen 50 (PSA50) response

    PSA50 response is defined as the proportion of patients who have a more/equal 50% decrease in PSA from baseline, it will be calculated at 12, 24 and 48 months

    Time frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

  2. Number of participants with Treatment Emergent Adverse Events

    The distribution of adverse events (AE) will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From enrollment till 30 days safety follow-up, assessed up to 50 months (estimated final OS analysis)

  3. Dosimetry Data of Tumor and Organs

    Absorbed Dose of 177Lu-P17-088 for Internal Irradiation in Tumors and Organs Based on SPECT/CT

    Time frame: After administration of 177Lu-P17-088, serial SPECT/CT scans are acquired at Day 0, Day 1, Day 2, Day 3, Day5, and absorbed dose is calculated based on these images.

Secondary outcomes

  1. Progression Free Survival (PFS)

    PSA-PFS is defined as the time from date of enrollment to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first.

    Time frame: From date of enrollment until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)

  2. Overall Survival (OS)

    OS is defined as time to death for any cause.

    Time frame: From date of enrollment until date of death from any cause, assessed up to 50 months (estimated final OS analysis)

Other outcomes

  1. Time to Response (TTR)

    TTR is defined as the time from the date of enrollment to the date of first documented response (CR or PR).

    Time frame: From date of enrollment till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 14 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2027 → Jun 2027 and completion Dec 2028 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 1, 2026
StartActual
Apr 29, 2026
Primary completionEst.
Jun 30, 2027was Dec 2027
CompletionEst.
Dec 31, 2027was Dec 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 27, 2026
Primary completion
Dec 31, 2027→Jun 30, 2027
Oct 27, 2026
Study completion
Dec 31, 2028→Dec 31, 2027
Oct 27, 2026
Enrollment
20 (estimated)→25 (actual)
Oct 27, 2026
Eligibility
3 inclusion criteria edited, 2 added, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedMetastatic Castration-Resistant Prostate Cancermetastatic androgen pathway modulation resistant (mCRPCmAPMR) mCRPCprostate cancer refers to prostateProstate cancer that progresses despite serum testosterone atwith distant metastases and sustained castrate levelstestosterone (< 50 ng/dL or 1.7 nmol/L) during APM therapy, meeting at least one of the following criteria≥1 criterion:
  • RemovedPSA >1 ng/mL with two consecutive rises at least 1 week apart, each increase ≥ 50% above the nadir.
  • RemovedRadiographic progression: Either two or more new bone lesions on bone scan, or soft tissue lesion progression as per RECIST 1.1 criteria. Progression based on symptoms alone is insufficient for mCRPC diagnosis and requires further evaluation.
  • AddedPSA nadir ≥1.0 ng/mL, absolute PSA rise ≥0.2 ng/mL confirmed ≥21 days apart;
  • AddedRadiographic progression: RECIST 1.1 soft tissue progression, or bone scan progression per PCWG4 2+2 rule (≥6 new bone lesions confirmed on single scan); PSMA-PET new metastatic lesions also qualify as progression.
  • EditedAt least one measurable soft tissue lesion per RECIST version 1.1 criteria, OR at least one bone metastasis per PCWG3 criteriaon bone scintigraphy, OR at least one PSMA-positive metastatic lesion on PSMA-PET/CT, all as defined by PCWG4.
  • EditedBone Marrow Function: Neutrophil count ≥ 1.5 × 10#\^9/L, White blood cell count ≥ 3.0 × 10\^9/L, Platelet count ≥ 100 × 10\^9/L, Hemoglobin ≥ 10 g/dL (≥ 100 g/L).
Oct 27, 2026
Primary outcomes
1 added
What changed in the outcomes
  • AddedDosimetry Data of Tumor and OrgansTime frame: After administration of 177Lu-P17-088, serial SPECT/CT scans are acquired at Day 0, Day 1, Day 2, Day 3, Day5, and absorbed dose is calculated based on these images.
Oct 27, 2026
Title
ProspectivePhase 2 Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistantfor mAPMR Prostate Cancer
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 31, 2027→Jun 30, 2027
    Study completion Dec 31, 2028→Dec 31, 2027
    Enrollment 20 (estimated)→25 (actual)
    Eligibility 3 inclusion criteria edited, 2 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedMetastatic Castration-Resistant Prostate Cancermetastatic androgen pathway modulation resistant (mCRPCmAPMR) mCRPCprostate cancer refers to prostateProstate cancer that progresses despite serum testosterone atwith distant metastases and sustained castrate levelstestosterone (< 50 ng/dL or 1.7 nmol/L) during APM therapy, meeting at least one of the following criteria≥1 criterion:
    • RemovedPSA >1 ng/mL with two consecutive rises at least 1 week apart, each increase ≥ 50% above the nadir.
    • RemovedRadiographic progression: Either two or more new bone lesions on bone scan, or soft tissue lesion progression as per RECIST 1.1 criteria. Progression based on symptoms alone is insufficient for mCRPC diagnosis and requires further evaluation.
    • AddedPSA nadir ≥1.0 ng/mL, absolute PSA rise ≥0.2 ng/mL confirmed ≥21 days apart;
    • AddedRadiographic progression: RECIST 1.1 soft tissue progression, or bone scan progression per PCWG4 2+2 rule (≥6 new bone lesions confirmed on single scan); PSMA-PET new metastatic lesions also qualify as progression.
    • EditedAt least one measurable soft tissue lesion per RECIST version 1.1 criteria, OR at least one bone metastasis per PCWG3 criteriaon bone scintigraphy, OR at least one PSMA-positive metastatic lesion on PSMA-PET/CT, all as defined by PCWG4.
    • EditedBone Marrow Function: Neutrophil count ≥ 1.5 × 10#\^9/L, White blood cell count ≥ 3.0 × 10\^9/L, Platelet count ≥ 100 × 10\^9/L, Hemoglobin ≥ 10 g/dL (≥ 100 g/L).
    Primary outcomes 1 added
    What changed in the outcomes
    • AddedDosimetry Data of Tumor and OrgansTime frame: After administration of 177Lu-P17-088, serial SPECT/CT scans are acquired at Day 0, Day 1, Day 2, Day 3, Day5, and absorbed dose is calculated based on these images.
    Title ProspectivePhase 2 Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistantfor mAPMR Prostate Cancer
    + 4 other changes: verification date, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07562438
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Responsible party
Sponsor
First posted
May 1, 2026
Start date
Apr 29, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Weibing Miao, MD
study chair · Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion